About: YM Biosciences     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Organisation, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FYM_Biosciences&invfp=IFP_OFF&sas=SAME_AS_OFF

YM BioSciences Inc. was a Canadian drug development company primarily focused on advancing CYT-387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. YM BioSciences also had several preclinical programs underway with candidates from its library of compounds identified through internal research conducted at YM BioSciences Australia.

AttributesValues
rdf:type
rdfs:label
  • YM Biosciences (en)
rdfs:comment
  • YM BioSciences Inc. was a Canadian drug development company primarily focused on advancing CYT-387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. YM BioSciences also had several preclinical programs underway with candidates from its library of compounds identified through internal research conducted at YM BioSciences Australia. (en)
foaf:name
  • YM BioSciences (en)
foaf:homepage
name
  • YM BioSciences (en)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
defunct
fate
  • Merged into Gilead Sciences (en)
foundation
founders
  • David Allan (en)
  • Tarrnie Williams (en)
homepage
  • www.ymbiosciences.com (en)
industry
location city
location country
products
revenue
  • $21 million In 2012 (en)
successor
has abstract
  • YM BioSciences Inc. was a Canadian drug development company primarily focused on advancing CYT-387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. YM BioSciences also had several preclinical programs underway with candidates from its library of compounds identified through internal research conducted at YM BioSciences Australia. The company also advanced other clinical-stage products, including Nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting agent (VDA). The company was listed on the Toronto Stock Exchange and the New York Stock Exchange. YM BioSciences was the first company from any major-market country to enter into a relationship with the Cuban Government for the development of a number of that country's biopharmaceuticals, with first licenses concluding in 1995. In 1994, the company created a joint venture with Centro de InmunologĂ­a Molecular (CCIMAB) in Cuba called CIMYM BioSciences. The joint venture developed the Nimotuzumab drug. In February 2013, Gilead Sciences completed the acquisition of YM Biosciences for US$510 million. (en)
prov:wasDerivedFrom
page length (characters) of wiki page
fate
  • Merged intoGilead Sciences (en)
founding year
revenue ($)
founded by
industry
product
successor
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is known for of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 60 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software